Omeros Corp (OMER) Receives a Hold from Wedbush

By Carrie Williams

Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros Corp (OMERResearch Report) today and set a price target of $18.00. The company’s shares closed last Monday at $16.91.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -13.1% and a 30.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.

Omeros Corp has an analyst consensus of Moderate Buy, with a price target consensus of $28.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros Corp has an average volume of 413.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.